nach oben

Current Dermatology Reports

Erschienen in:

05.11.2019 | Psoriasis (J Wu, Section Editor)

Review of Outcome Measures in Trials and Practice for Psoriasis

Erschienen in: Current Dermatology Reports | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review was to determine the most frequently utilized outcome measures in clinical trials and to review the scoring criteria, advantages, disadvantages, and application in research and clinical settings, as well as provide an overview of the published guidelines on the use of outcome measures in clinical practice.

Recent Findings

The most frequently utilized physician-reported outcome measurement instruments in clinical trials from 2018 to 2019 were Physician Global Assessment (PGA), Psoriasis Area Severity Index (PASI), and body surface area. The most frequently utilized patient-reported outcome measurement instruments were Dermatology Quality of Life Index, EQ-5D-5L, and patient global assessment.

Summary

In research, further standardization of outcome measures may allow for more useful comparison of different treatment modalities. In clinical practice, although, the PASI provides a detailed measurement of disease severity, and the PGA score has the advantage of being more clinically useful to physicians and patients.

Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–20. https://doi.org/10.1046/j.1365-2230.2001.00832.x.PubMedCrossRef

Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94. https://doi.org/10.1016/S0140-6736(14)61909-7.PubMedCrossRef

Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies. Clin Dermatol. 2010;28(1):67–72. https://doi.org/10.1016/j.clindermatol.2009.03.001.PubMedCrossRef

Feldman S, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl 2):ii65–i8.PubMedPubMedCentral

Poór AK, Rencz F, Brodszky V, Gulácsi L, Beretzky Z, Hidvégi B, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res. 2017;26(12):3409–19.PubMedCrossRef

Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol. 2006;155(4):707–13.PubMedCrossRef

Loo W, Diba V, Chawla M, Finlay A. Dermatology life quality index: influence of an illustrated version. Br J Dermatol. 2003;148(2):279–84.PubMedCrossRef

Basra M, Fenech R, Gatt R, Salek M, Finlay A. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.PubMed

Langenbruch A, Radtke M, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol. 2019;33(1):123–7.PubMedCrossRef

10.

Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194–9.PubMedCrossRef

11.

Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23–31.CrossRef

12.

Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004;51(4):563–9.PubMedCrossRef

13.

Feldman S. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat. 2004;15(1):27–9.CrossRef

14.

Po LW. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185–91.CrossRef

15.

Long C, Finlay A, Averill R. The rule of hand: 4 hand areas= 2 FTU= 1 g. Arch Dermatol. 1992;128(8):1129–30.PubMedCrossRef

16.

Stern RS, Armstrong RB, Anderson TF, Bickers DR, Lowe NJ, Harber L, et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J Am Acad Dermatol. 1986;15(3):546–52.PubMedCrossRef

17.

• Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8 This is a consensus paper that provides guidelines on what outcome measurements to use endrosed by the National Psoriasis Foundation. This is important as it is a well-known professional soceity offereing guidance on this topic. PubMedCrossRef

18.

Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: a work in progress. Cutis. 2018;101(3S):10–2.PubMed

19.

• Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJ, Bertheussen H, et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheum. 2018;70(3):345–55 This paper provided consenses from GRAPPA’s meeting to disucss recommendations for use of measurements and treatment targets. This is important as it provides additional guidelines for which outcome measurements to use. CrossRef

20.

Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths C, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.PubMedCrossRef

21.

Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:10–6.PubMedCrossRef

22.

Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001;45(1):72–6.PubMedCrossRef

23.

• Wechter T, Heath M, Aung-Din D, Sahni D, Cline A, Feldman SR. Current psoriasis efficacy outcome measures in clinical trials. Curr Dermatol Rep. 2018;7(4):261–8 This paper is a review paper in which studied the outcome measurements from 2017–2018. The methods was very similar to the methods used for this paper; however, we incorportated clinical practice guidelines and reviewed measurements for 2018–2019. CrossRef

24.

Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151(4):375–81.PubMedCrossRef

Titel: Review of Outcome Measures in Trials and Practice for Psoriasis
Publikationsdatum: 05.11.2019
Erschienen in: Current Dermatology Reports / Ausgabe 4/2019
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-019-00283-0

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Review of Outcome Measures in Trials and Practice for Psoriasis

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Photoallergic Contact Dermatitis

Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update

Inpatient Management of Mucocutaneous GVHD

An Approach to Retiform Purpura for the Inpatient Dermatologist

Non-invasive Imaging for Skin Cancers—the European Experience

Screening and Managing Melanoma: Who Is (Should Be) Doing It?

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie